stockrowAmgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −0.16%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) Total debt
Amgen Inc.'s total debt at the end of fiscal 2025 was $54.6B, down 9.14% from $60.1B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $54.0B. Over the past ten years it has ranged from $29.9B (fiscal 2019) to $64.6B (fiscal 2023); the current reading is higher than 82% of that period. Amgen Inc. ranks 3rd of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $54.6B | (9.14%) |
| FY2024 | $60.1B | (6.99%) |
| FY2023 | $64.6B | 65.91% |
| FY2022 | $38.9B | 16.92% |
| FY2021 | $33.3B | 0.98% |
| FY2020 | $33.0B | 10.31% |
| FY2019 | $29.9B | (11.87%) |
| FY2018 | $33.9B | (4.00%) |
| FY2017 | $35.3B | 2.16% |
| FY2016 | $34.6B | 10.08% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $54.0B | (5.75%) |
| Jun 2026 | $57.3B | (0.03%) |
| Mar 2026 | $57.3B | 4.98% |
| Dec 2025 | $54.6B | 0.03% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ABBV AbbVie Inc. compare | $80.9B |
| PFE Pfizer Inc. compare | $62.7B |
| AMGN Amgen Inc. | $54.0B |
| MRK Merck & Co., Inc. compare | $51.1B |
| NVS Novartis AG compare | $46.3B |
| BMY Bristol Myers Squibb Company compare | $42.9B |
| AZN AstraZeneca PLC compare | $31.4B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| NVO Novo Nordisk A/S compare | $21.8B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement